Boosting the Exhausted Vasculature—SIRT3 (to the) Rescue

[1]  R. Tuder,et al.  SIRT3 Is a Critical Regulator of Mitochondrial Function of Fibroblasts in Pulmonary Hypertension. , 2023, American journal of respiratory cell and molecular biology.

[2]  P. Zimmer,et al.  Tissue‐specific effects of exercise as NAD+‐boosting strategy: Current knowledge and future perspectives , 2023, Acta physiologica.

[3]  C. Ruppert,et al.  Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension , 2022, Science Translational Medicine.

[4]  J. Qu,et al.  SIRT3 consolidates heterochromatin and counteracts senescence , 2021, Nucleic acids research.

[5]  G. Kroemer,et al.  Nicotinamide for the treatment of heart failure with preserved ejection fraction , 2021, Science Translational Medicine.

[6]  S. Erzurum,et al.  Metabolism in Pulmonary Hypertension. , 2021, Annual review of physiology.

[7]  J. Barberà,et al.  Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. , 2020, European heart journal.

[8]  R. Tuder,et al.  Stable isotope metabolomics of pulmonary artery smooth muscle and endothelial cells in pulmonary hypertension and with TGF-beta treatment , 2020, Scientific Reports.

[9]  F. Cheng,et al.  Integrative proteomics and phosphoproteomics in pulmonary arterial hypertension , 2019, Scientific Reports.

[10]  P. Carmeliet,et al.  Identification of MicroRNA-124 as a Major Regulator of Enhanced Endothelial Cell Glycolysis in Pulmonary Arterial Hypertension via PTBP1 (Polypyrimidine Tract Binding Protein) and Pyruvate Kinase M2 , 2017, Circulation.

[11]  P. Ježek,et al.  Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124/PTBP1 (Polypyrimidine Tract Binding Protein 1)/Pyruvate Kinase Muscle Axis , 2017, Circulation.

[12]  James D. Thomas,et al.  Metabolic and Functional Evaluation of the Heart and Lungs in Pulmonary Hypertension by Gated 2-[18F]-Fluoro-2-deoxy-D-glucose Positron Emission Tomography , 2017, Pulmonary circulation.

[13]  J. Loscalzo,et al.  Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. , 2016, The Journal of clinical investigation.

[14]  S. Pullamsetti,et al.  Constitutive Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension. , 2016, American journal of respiratory cell and molecular biology.

[15]  S. Provencher,et al.  Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. , 2014, Cell metabolism.

[16]  L. Gleaves,et al.  Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. , 2014, American journal of respiratory and critical care medicine.

[17]  J. Marks,et al.  Sirtuin 3 deficiency does not augment hypoxia-induced pulmonary hypertension. , 2013, American journal of respiratory cell and molecular biology.

[18]  S. Pullamsetti,et al.  Heterogeneity in Lung 18FDG Uptake in Pulmonary Arterial Hypertension: Potential of Dynamic 18FDG Positron Emission Tomography With Kinetic Analysis as a Bridging Biomarker for Pulmonary Vascular Remodeling Targeted Treatments , 2013, Circulation.

[19]  Enxuan Jing,et al.  Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production , 2011, Proceedings of the National Academy of Sciences.

[20]  P. Harris.  Editorials , 1911, Paraplegia.